SIRPA and hematologic disorder: The CD47/SIRPα signaling pathway through CD47 interacting with SIRPα on macrophages and dendritic cells, is an attractive target for cancer therapies in both solid tumors and hematological malignancies by regulating normal immune tolerance and autoimmunity (4, 7–10).